Charts

News

16 Apr, 2024
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Blackstone Inc (BX), where a total of 31,640 contracts have traded so far, representing approximately 3.2 million underlying shares. That amounts to about 110.5% of BX's average daily trading volume over the past month of 2.9 million shares..
Investors in Cassava Sciences Inc (SAVA) saw new options begin trading this week, for the May 31st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SAVA options chain for the new May 31st contracts and identified one put and one call contract of particular interest.
15 Apr, 2024
Monday, May 6, 2024 is Last and Final Day to Exercise Warrants.Once Redeemed, the Warrants Will Cease to Exist and Have No Value. AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (“Cassava Sciences” or the "Company") today announced that Monday, May 6, 2024 is the last and final day to exercise the warrants that were previously distributed to its shareholders on January 3, 2024 (the “Warrants”). Holders who exercise their Warrants will receive 1.5 shares of
12 Apr, 2024
Shares of JPMorgan Chase & Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings. Net ...
08 Apr, 2024
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Cassava Sciences Inc (SAVA), where a total volume of 3,233 contracts has been traded thus far today, a contract volume which is representative of approximately 323,300 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 48.4% of SAVA's average daily trading volume over the past month, of 667,300 shares..
01 Apr, 2024
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Growth ETF (VTWG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $228.62 per unit.
25 Mar, 2024
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials Continue as Planned, Without Modification. Final Clinical Safety Data for Simufilam Are Expected at the Conclusion of the Phase 3 Program. AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced th
21 Mar, 2024
Cassava Sciences's (NYSE:SAVA) short percent of float has fallen 3.46% since its last report. The company recently reported that it has ...
12 Mar, 2024
The credibility of the clinical trial results for an experimental Alzheimer’s drug has been called into question following a ...
On Monday, the U.S. stock market presented a mixed performance. The Dow Jones index managed to turn higher, trading up by 0.12% to ...
07 Mar, 2024
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in OneSpan Inc (OSPN), where a total of 1,182 contracts have traded so far, representing approximately 118,200 underlying shares. That amounts to about 46.2% of OSPN's average daily trading volume over the past month of 255,985 shares..
06 Mar, 2024
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..
Quite a few insiders have dramatically grown their holdings in Cassava Sciences, Inc. ( NASDAQ:SAVA ) over the past 12...
04 Mar, 2024
AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced plans to present a virtual oral presentation at the International Conference on Alzheimer’s and Parkison’s Disease (AD/PD 2024) taking place in Lisbon, Portugal from March 5-9, 2024. Presentation details Title: Oral Simufilam in Mild-to-moderate Alzheimer’s Disease: Baseline Characteristics in RETHINK and REFOCUS Phase 3 T
29 Feb, 2024
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Pharmaceuticals ETF (XPH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $60.42 per unit.
28 Feb, 2024
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in 3D Systems Corp. (DDD), where a total volume of 29,522 contracts has been traded thus far today, a contract volume which is representative of approximately 3.0 million underlying shares (given that every 1 contract represents 100 underlying shares)..
Cassava Sciences (NASDAQ:SAVA) reported its Q4 earnings results on Wednesday, February 28, 2024 at 09:14 AM. Here's what investors need ...
Key Financials and Corporate Updates Highlighted
$121.1 Million In Cash and Cash Equivalents at December 31, 2023, With an Additional $21.8 Million Raised In 2024 From Exercise of Warrants.A Total of Over 555 Study Participants Have Completed Our Phase 3 Studies.Topline Data Readout for Our 52-Week Phase 3 Trial Expected Year-End 2024.Internal Investigation by Outside Counsel Has Found No Evidence to Substantiate Allegations of Research Misconduct by the Company. AUSTIN, Texas, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq:
21 Feb, 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips These biotech stocks to sell represent incredibly risky bets, amidst the sector's volatility and looming economic unpredictability. The post Exit Now! 3 Biotech Stocks to Sell in February 2024 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.
In trading on Wednesday, shares of Cassava Sciences Inc (SAVA) crossed below their 200 day moving average of $21.98, changing hands as low as $21.88 per share. Cassava Sciences Inc shares are currently trading off about 1.6% on the day..
11 Feb, 2024
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA) and certain of its officers.
08 Feb, 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips WiMi Hologram Cloud stock is taking off on Thursday with speculative trading as it rallies alongside another Chinese hologram company. The post Why Is WiMi Hologram Cloud (WIMI) Stock Up 22% Today? appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips MicroCloud Hologram stock is taking off on Thursday as speculative traders continue to bet on HOLO shares following a recent rally. The post MicroCloud Hologram (HOLO) Stock Pops Another 10% in Speculative Rally appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips SAVA stock jumped 9% on Wednesday after Casava Sciences shared promising results of a clinical trial of its Alzheimer's treatment. The post Cassava Sciences (SAVA) Stock Pops on Positive Results in Simufilam Trial appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.
07 Feb, 2024
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Cassava Sciences Inc (SAVA), where a total of 6,243 contracts have traded so far, representing approximately 624,300 underlying shares. That amounts to about 86.8% of SAVA's average daily trading volume over the past month of 718,830 shares..
Cassava Sciences, Inc. (NASDAQ:SAVA) shares are trading higher Wednesday after the company reported top-line results of a two-year ...
ADAS-Cog Scores Were Stable in a Group of Patients with Mild Alzheimer’s Who Received Drug Candidate Simufilam Continuously, Baseline to Month 24.Mild Alzheimer’s Patients Who Received Simufilam Non-Continuously Declined a Group Average of 1 Point on ADAS-Cog, Baseline to Month 24.Oral Simufilam Safe, Well-Tolerated. AUSTIN, Texas, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today reported top-line results of a two-year clinical safety study
05 Feb, 2024
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between August 18, 2022 and October 12, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 2, 2024.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..
Key Insights Cassava Sciences' significant retail investors ownership suggests that the key decisions are influenced by...
03 Feb, 2024
Battered by controversy, this company will need to show real results to prosper.
25 Jan, 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The biotech industry is one of the most profitable though risky at the same time. Here are three biotech stocks to sell. The post 3 Biotech Stocks to Sell in January Before They Crash and Burn appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.
16 Jan, 2024
On Tuesday, Cassava Sciences reached an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 90-plus percentile with an improvement to 92, up from 87 the previous trading day. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. Cassava Sciences stock has recently cleared several key moving averages.
05 Jan, 2024
Shareholders of Record Received Warrants to Purchase Shares of Common Stock Warrants Trade on Nasdaq Under the Ticker “SAVAW”Warrant Holders Who Choose to Exercise During an Early Period Will Receive an Additional 0.5 of a Common Share Per Warrant AUSTIN, Texas, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) ("Cassava Sciences" or the "Company") today announced the completion of a previously announced distribution of warrants (the “Warrants”) to its shareholders. The War
26 Dec, 2023
Wall Street analysts foresee up to 316% upside in three fast-paced companies in the new year.
21 Dec, 2023
20 Dec, 2023
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
15 Dec, 2023
The company has chosen an offbeat way to keep its investors sweet.
13 Dec, 2023
Cassava Sciences saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, with an upgrade from 79 to 88. The company earns the No. 172 rank among its peers in the Medical-Biomed/Biotech industry group.
12 Dec, 2023
Shareholders of Record Will Receive Warrants to Purchase Shares of Common Stock All Warrants to Be Distributed to Shareholders Free of ChargeWarrants Are Expected to List and Trade on NasdaqWarrant Holders Who Choose to Exercise During an Early Period Will Also Receive an Additional 0.5 of a Common Share Per Warrant AUSTIN, Texas, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) ("Cassava Sciences" or the "Company") today announced a pro rata dividend distribution of warra
09 Dec, 2023
Ambitious biotech Cassava Sciences (NASDAQ: SAVA) had a fine Friday on the stock market, with its shares closing more than 17% higher. Cassava, which concentrates its efforts on treatments for Alzheimer's disease, said that it had appointed three new members to its board of directors. Of the trio, two are seasoned veterans in the healthcare industry, and the third has notable experience in cybersecurity and emergency-response management.
07 Dec, 2023
Dr. Nicaise, Mr. Gravier and Mr. Anderson have years of experience in drug development, healthcare M&A and working with the U.S. GovernmentAUSTIN, Texas, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the appointment of three new members to its Board of Directors, effective immediately. Claude Nicaise, MD – Dr. Nicaise has held clinical/regulatory leadership roles that have resulted i
24 Aug, 2023

Related Articles